Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of a phase II trial

Japanese Journal of Clinical Oncology

Volumn 43, Issue 5, 2013, Pages 524-531

  Yoshino, Takayuki ^a   Hasegawa, Yasuhisa ^b   Takahashi, Shunji ^c   Monden, Nobuya ^d   Homma, Akihiro ^e   Okami, Kenji ^f   Onozawa, Yusuke ^g   Fujii, Masato ^h   Taguchi, Takahide ⁱ   de Blas, Barbara ^j   Beier, Frank ^j   Tahara, Makoto ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^f TOKAI UNIVERSITY HOSPITAL   (Japan)

^g SHIZUOKA CANCER CENTER   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

ⁱ YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^j MERCK KGAA   (Germany)

more..

Author keywords

Cetuximab; Chemotherapy; Head and neck; Phase II trial; Squamous cell carcinoma

Indexed keywords

CETUXIMAB; CISPLATIN; FLUOROURACIL; K RAS PROTEIN;

ACNE; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DERMATITIS; DERMATITIS ACNEIFORM; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGUS FISTULA; FAINTNESS; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHARYNX CARCINOMA; JAPANESE; LARYNX CARCINOMA; LEUKOPENIA; LIMIT OF QUANTITATION; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SEPTIC SHOCK; SIDE EFFECT; STAPHYLOCOCCAL BACTEREMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84877357374     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt034     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Sofue T, Miki W, Matsuda T, Marugame T. Monitoring of Cancer Incidence in Japan (MCIJ 2006) Tokyo, Japan: Center for Cancer Control and Information Service, National Cancer Center.
3. Cancer mortality (1958-2009). Center for Cancer Control and Information Services, National Cancer Center. http://ganjoho.jp/data/professional/statistics/odjrh3000000hwsa-att/cancer_mortality(1958- 2009).xls. (23 May 2011, date accessed).
4. Clinical Oncology Update-Essentials for the Medical Oncologist. 2nd edn. Japanese Society of Medical Oncology. Tokyo, Japan: Nankodo 2009.
5. Christensen ME, Therkildsen MH, Hansen BL, Albeck H, Hansen GN, Bretlau P. Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas. Eur Arch 1992;249:243-7.
6. Fujii S, Uryu H, Akashi K, et al. Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. Int J Clin Oncol 2012 [epub 24 March 2012 ahead of print].
7. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-92.
8. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
9. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v184-6.
10. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers National Comprehensive Cancer Network, Inc. http://www.nccn.org.
11. Head and Neck Cancer In: Residents of internal medicine of National Cancer Center. Resident manual for clinical practice on cancer. 5th edn. Tokyo, Japan: IGAKU-SHOIN Ltd 2010;275-86.
12. Skeel RT, Furue H, Tsukagoshi S. Head and Neck Cancer. In: Cancer chemotherapy handbook. 6th edn. Tokyo, Japan: Medical Science International Co., Ltd 2009;177-93.
13. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009;15:4806-14.
14. Watanabe A, Taniguchi M, Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anticancer Drugs 2003;14:801-7.
15. Kiyota N, Tahara M, Okano S, et al. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 2012;42:927-33.
16. Zenda S, Onozawa Y, Tahara M, et al. Feasibility study of single agent cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. Jpn J Clin Oncol 2007;37:725-9.
17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
18. Fujii M, Yoshino T, Onozawa Y, et al. Phase II study of cetuximab with concomitant-boost radiotherapy (RT) in Japanese patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Eur J Cancer 2011;47 (Suppl 1):S564-5 (Abstract 8570).
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
20. Shirao K, Yoshino T, Boku N, et al. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2009;64:557-64.
21. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663- 71.
22. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
23. Anderson JA, Irish JC, Ngan BY. Prevalence of RAS oncogene mutation in head and neck carcinomas. J Otolaryngol 1992;21:321-6.
24. Rathcke IO, Gottschlich S, Gorogh T, Lippert BM, Werner JA. Incidence of point mutations in Ki-ras codon 12 and 13 in squamous epithelial carcinomas of the head-neck region. Laryngorhinootologie 1996;75:465-70.
25. Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM. Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994;104:1337-47.